I.V. Selonabant in Healthy Adult Subjects

Phase 1 Completed 40 enrolled Anebulo Pharmaceuticals National Institute on Drug Abuse (NIDA) · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years

Timeline

Start: 2025-09-22
Primary completion: 2026-05-06
Completion: 2026-05-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	selonabant	Small molecule	1 mg	Intravenous
Subject	selonabant	Small molecule	2 mg	Intravenous
Subject	selonabant	Small molecule	5 mg	Intravenous
Subject	selonabant	Small molecule	10 mg	Intravenous
Subject	selonabant	Small molecule	20 mg	Intravenous

Indications

No indication recorded.